Prospective Evaluation of Two iStent® Trabecular Stents, One iStent Supra® Suprachoroidal Stent, and Postoperative Prostaglandin in Refractory Glaucoma: 4-year Outcomes

Abstract

Introduction: This study evaluates long-term outcomes of two trabecular micro-bypass stents, one suprachoroidal stent, and postoperative prostaglandin in eyes with refractory open angle glaucoma (OAG).

Methods: Prospective ongoing 5-year study of 80 eligible subjects (70 with 4-year follow-up) with OAG and IOP ≥ 18 mmHg after prior trabeculectomy and while taking 1-3 glaucoma medications. Subjects received two iStent® trabecular micro-bypass stents, one iStent Supra® suprachoroidal stent, and postoperative travoprost. Postoperative IOP was measured with medication and annually following medication washouts. Performance was measured by the proportion of eyes with ≥ 20% IOP reduction on one medication (the protocol-specified prostaglandin) versus preoperative medicated IOP (primary outcome); and the proportion of eyes with postoperative IOP ≤ 15 and ≤ 18 mmHg on one medication (secondary outcome). Additional clinical and safety data included medications, visual field, pachymetry, gonioscopy, adverse events, visual acuity, and slit-lamp and fundus examinations.

Results: Preoperatively, mean medicated IOP was 22.0 ± 3.1 mmHg on 1.2 ± 0.4 medications, and mean unmedicated IOP was 26.4 ± 2.4 mmHg. Postoperatively, among eyes without later cataract surgery, mean medicated IOP at all visits through 48 months was ≤ 13.7 mmHg (≥ 37% reduction), and annual unmedicated IOP was ≤ 18.4 mmHg (reductions of ≥ 30% vs. preoperative unmedicated IOP and ≥ 16% vs. preoperative medicated IOP). At all postoperative visits among eyes without additional surgery or medication, ≥ 91% of eyes had ≥ 20% IOP reduction on one medication versus preoperative medicated IOP. At month 48, 97 and 98% of eyes achieved IOP ≤ 15 and ≤ 18 mmHg, respectively, on one medication. Six eyes required additional medication, no eyes required additional glaucoma surgery, and safety measurements were favorable throughout follow-up.

Conclusion: IOP control was achieved safely with two trabecular micro-bypass stents, one suprachoroidal stent, and postoperative prostaglandin. This microinvasive, ab interno approach introduces a possible new treatment option for refractory disease.

Trial registration: NCT01456390.

Funding: Glaukos Corporation.

Keywords: Glaucoma; Microinvasive glaucoma surgery (MIGS); Ophthalmology; Prostaglandin; Refractory glaucoma; Suprachoroidal; Trabecular; iStent; iStent Supra.

Figures

Fig. 1

iStent® trabecular micro-bypass

Fig. 2

iStent Supra® suprachoroidal micro-bypass

Fig. 3

Mean IOP over time. *Unmedicated IOP (at months 13, 25, 37, 49) was assessed after 1-month washout. aExcludes data after additional surgery (either glaucoma surgery [n = 0] or cataract surgery [n = 10]). IOP Intraocular pressure, SD Standard deviation, SCR screening, BL baseline, M month

Fig. 4

Proportional analysis of postoperative IOP reduction ≥ 20%. *Unmedicated IOP (at months 13, 25, 37, 49) was assessed after 1-month washout. aExcludes data after cataract surgery (n = 10). Subjects with additional glaucoma surgery (n = 0) or addition of a second ocular hypotensive medication (n = 6) were considered non-responders. IOP Intraocular pressure, Med medication, Preop preoperative, M month

Fig. 5

Proportional analysis of postoperative IOP ≤ 15 and ≤ 18 mmHg. aExcludes data after cataract surgery (n = 10). Subjects with additional glaucoma surgery (n = 0) or addition of a second ocular hypotensive medication (n = 6) were considered non-responders. IOP Intraocular pressure, Med medication, M month

Fig. 6

Preoperative versus month 48 best-corrected visual acuity (BCVA)